← All trials
NCT03331718
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2018
- Primary completion
- May 1, 2021
- Completion date
- May 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 514
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ToyamaLead sponsor
- Seoul National UniversityCollaborator
- Sungkyunkwan UniversityCollaborator
- Yonsei UniversityCollaborator
- Kansai Medical UniversityCollaborator
- Kumamoto UniversityCollaborator
- Nagoya UniversityCollaborator
- Nara Medical UniversityCollaborator
- National Cancer Center, KoreaCollaborator
- Osaka City UniversityCollaborator
- Osaka UniversityCollaborator
- China Medical UniversityCollaborator
- Shimane UniversityCollaborator
- Tokyo Medical and Dental UniversityCollaborator
- Tokyo Medical UniversityCollaborator
- Wakayama Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.